To determine whether targeting RAB10 in SMAD4-deficient colorectal and pancreatic cancers would exhibit a therapeutic value in the long run, further efforts are also necessary to develop inhibitors specifically targeting RAB10. Here, SMAD4 is linked to pancreatic neoplasm.